Ameela Eyes

Polynucleotide injectable skin booster

Under-eye polynucleotide biostimulatory gel (injectable)

CE Marked polynucleotide injectable product for aesthetic use within the European/UK market
Manufactured under medical device quality systems consistent with ISO 13485 (as stated for the Ameela polynucleotide range)
Produced using highly purified wild salmon DNA with traceability through an approved agri Food supply chain
Marketed to medical professionals for use in accordance with local medical device and aesthetic practice regulations

CE Marked polynucleotide injectable product for aesthetic use within the European/UK market
Manufactured under medical device quality systems consistent with ISO 13485 (as stated for the Ameela polynucleotide range)
Produced using highly purified wild salmon DNA with traceability through an approved agri Food supply chain
Marketed to medical professionals for use in accordance with local medical device and aesthetic practice regulations

Under-eye polynucleotide biostimulatory gel (injectable)

Description

Ameela Eyes is a specialised under-eye biostimulatory treatment based on polymerised polynucleotides, developed specifically for the delicate periocular area. The sterile, viscoelastic polynucleotide gel is derived from highly purified wild salmon DNA and is designed to deeply hydrate, revitalise and restructure the under-eye skin without adding volume like a filler. By promoting microcirculation, blocking free radicals and stimulating tissue regeneration, Ameela Eyes helps to reduce dark circles, puffiness and fine lines, while improving elasticity, texture and overall skin quality around the eyes. It can be used as a stand-alone cosmetic injectable or in combination with other aesthetic procedures, including as a pre- and post-surgical adjunct to treatments such as blepharoplasty and resurfacing lasers.

Bnefits

Targets common under-eye concerns including dark circles, puffiness, fine lines and early periocular ageing
Provides deep, long-lasting hydration to the thin, delicate under-eye skin
Improves skin texture, elasticity and firmness in the periocular region
Supports microcirculation, helping to brighten and refresh tired-looking under-eyes
Acts as an antioxidant, helping to neutralise free radicals and protect against oxidative stress
Promotes tissue regeneration and bio-restructuration rather than simple volumisation
Non-volumising biostimulator that preserves natural expression and contours
Viscoelastic, highly purified polynucleotide gel with high molecular weight chains for effective bio-stimulation
Suitable for use as a pre-/post-surgical supportive treatment around the eyes
CE-marked, professional-use-only injectable for medical aesthetic practitioners

Indications

Eye bags and under-eye puffiness
Dark circles and tired appearance of the under-eye area
Periocular fine lines and superficial wrinkles (crow’s feet, under-eye lines)
Dehydrated or crepey under-eye skin
Poor microcirculation in the periocular region
Early signs of periocular ageing and loss of elasticity
Adjunctive treatment around surgical procedures such as blepharoplasty, lifting and laser resurfacing (pre- and post-treatment support)

Composition

Polymerised polynucleotide (PDRN) gel derived from highly purified wild salmon DNA (approx. 20 mg total polynucleotides in a 2.5 ml syringe, ~8 mg/ml concentration)
High molecular weight polynucleotide chains (molecular weight ≥1000 KDa)
Physiological buffer system with pH between approximately 6.8 and 7.5
Viscoelastic gel with viscosity in the range of approximately 2–8 Pa·s
Excipients and water for injection suitable for sterile, non-pyrogenic injectable use
Free from protein impurities that could trigger significant immunogenic response (highly purified salmon DNA fragments)

Formulation

Viscoelastic, sterile, non-pyrogenic polynucleotide gel for injectable use
Polymerised polynucleotide (PDRN) formulation specifically engineered for the periocular area
Non-volumising biostimulatory gel acting via hydration, antioxidant activity and fibroblast stimulation
Injectable mesotherapy/skin-booster style product for intradermal or subdermal administration by trained professionals
CE-marked medical aesthetic product for professional use only

Packaging

Single pre-filled syringe containing approximately 2.5 ml of Ameela Eyes polynucleotide gel (current enhanced formulation)
Syringe supplied in a branded Ameela Eyes box with protective blister and labelling
Each unit labelled with batch/lot number, expiry date, contents and CE marking information
Designed for single-patient, single-use only; disposal of used syringes and needles according to sharps and clinical waste regulations

Usage

For professional medical aesthetic use only; treatment must be performed by a suitably trained healthcare practitioner experienced in injectable periocular procedures.
Review patient history, indications and contraindications, and obtain informed consent before treatment.
Cleanse and disinfect the periocular area thoroughly using an appropriate antiseptic, avoiding direct contact with the ocular surface.
If required, apply topical anaesthetic according to clinic protocol and manufacturer recommendations, then remove fully before injection.
Using a suitable fine needle or cannula (according to the practitioner’s chosen technique and local guidelines), inject small aliquots of the gel into the appropriate superficial or mid-dermal/subdermal planes of the under-eye and periocular region.
Common techniques include micro-depot, linear threading or fanning patterns along the orbital rim and under-eye area, taking care to avoid intravascular injection and to respect anatomical danger zones.
Gently massage the treated area if indicated to distribute the product evenly and minimise palpable irregularities, while avoiding excessive pressure.
A typical treatment course consists of approximately 2–3 sessions spaced around 2–3 weeks apart, adjusted according to skin quality and clinical judgement.
Advise the patient on post-treatment care, including avoiding makeup on the treated area for the recommended period, refraining from intense heat exposure (sunbeds, saunas) and heavy exercise for 24–48 hours, and not massaging or manipulating the area unless instructed.
Use appropriate aseptic technique throughout, and dispose of needles, syringes and consumables immediately after use in approved sharps containers.
Do not reuse any remaining product; the syringe is for single use only.

Contraindications

Known hypersensitivity or allergy to polynucleotides, salmon-derived products or any component of the formulation
Active skin infections, inflammation, dermatitis or herpetic lesions in or near the treatment area
Severe chronic inflammatory or autoimmune diseases affecting the planned treatment area, unless carefully evaluated and cleared by an appropriate specialist
History of severe anaphylactic reactions or multiple severe allergies (relative contraindication; requires individual risk–benefit assessment)
Pregnancy and breastfeeding (use is generally not recommended in the absence of robust safety data)
Uncontrolled systemic diseases or significant coagulation disorders that increase the risk of bleeding or bruising at injection sites
Use of anticoagulant or antiplatelet medications without appropriate medical assessment (relative contraindication)
Recent or planned major periocular surgery, laser resurfacing or other aggressive procedures in the same area that are not compatible with the recommended pre-/post-treatment intervals
Any condition or circumstance that, in the practitioner’s clinical judgement, makes injectable treatment of the under-eye area unsafe

Adverse Effects

Expected transient injection-site reactions such as redness, swelling, tenderness, warmth or mild discomfort in the treated area
Local bruising or small haematomas at injection points, particularly in the highly vascular periocular region
Temporary lumps, bumps or unevenness if product distribution is initially uneven (usually resolving as oedema subsides or with gentle massage by a practitioner)
Mild pruritus or sensitivity in the treated area during the immediate post-treatment period
Less commonly, more pronounced or prolonged swelling, particularly in patients prone to fluid retention or with pre-existing under-eye oedema
As with any injectable procedure, there is a low risk of infection, abscess formation or granulomatous reaction if aseptic technique is not strictly followed or in susceptible individuals
Very rare risk of intravascular injection or vascular compromise; practitioners must use appropriate technique and anatomical knowledge to minimise this risk and manage complications promptly if they occur
Any unusual, persistent or severe adverse event should be assessed and managed by a medical professional and reported according to local pharmacovigilance or device vigilance requirements

Storage Conditions

Store in a clean, dry place at a controlled room or refrigerated temperature consistent with the temperature range specified in the official product leaflet (commonly between 2°C and 25°C).
Protect from direct sunlight, excessive heat and humidity.
Do not freeze the product; freezing may damage the polynucleotide gel structure.
Keep the syringe in its original outer packaging until immediately before use to maintain sterility and protect from light.
Do not use after the expiry date printed on the packaging or if the blister or syringe appears damaged, leaking or contaminated.

Duration

Typically performed as a course of 2\u20133 treatment sessions spaced approximately 2\u20133 weeks apart, with results often maintained for several months (commonly around 6\u20139 months) before optional maintenance sessions once or twice per year, depending on individual skin condition and practitioner protocol.

Onset

Many patients notice early improvements in hydration and skin quality within the first few weeks after treatment; structural and textural benefits (such as reduced fine lines, less visible dark circles and improved elasticity) tend to build progressively over subsequent weeks and after completion of the treatment course.